Overview

• The settlement allocates $6.5 billion from the Sackler family and $900 million from Purdue Pharma over a 15-year schedule, with an initial $2.4 billion paid in the first three years.
• Funds will flow to states, local governments, Native American tribes and individual claimants to bolster addiction treatment, prevention and recovery efforts.
• As part of the agreement, Sackler family members must relinquish ownership of Purdue Pharma and are barred from future opioid sales in the United States.
• Individuals and entities can opt out of the settlement to preserve civil litigation rights against nonparticipating Sackler family members.
• A federal bankruptcy court hearing is set in the coming days before U.S. Bankruptcy Judge Sean Lane to confirm the deal’s reorganization plan.